Compare Crispr Therapeutics AG (CRSP) vs Illinois Tool Works Inc. (ITW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Illinois Tool Works Inc. — how do they compare? Crispr Therapeutics AG trades at $49.91 (market cap $4.97B), while Illinois Tool Works Inc. trades at $271.71 (market cap $78.33B). The key difference: Illinois Tool Works Inc. is far larger — about 15.8× Crispr Therapeutics AG's market cap, and Illinois Tool Works Inc. pays a 2.37% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | ITW | |
|---|---|---|
Market Cap | $4.97B | $78.33B |
Sector | Health | Industrials |
52-Week High | $76.78 | $299.60 |
52-Week Low | $44.34 | $241.07 |
Enterprise Value | $3.32B | $86.66B |
Dividend Yield | — | 2.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Illinois Tool Works (ITW) trades at $271.50, up 1.0% today, with a bullish technical signal from moving averages and a consensus analyst price target of $288.25. The company has consistently beaten earnings estimates in recent quarters, including Q1 2026 EPS of $2.66 versus $2.57 expected, and maintains strong profitability with a net income margin of 19.32% and ROE of 96.88%. Recent news highlights segment strength and a declared quarterly dividend of $1.61.
The outlook for ITW is positive, supported by earnings momentum and operational efficiency, though risks include construction sector weakness and currency headwinds. The stock offers a balanced opportunity with solid fundamentals and a dividend, but investors should weigh high valuation multiples against growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →
